
ETCTN Trials by Disease/Treatment Area: Gastrointestinal Cancer



NOTE: ▼ Limited trial; not open ETCTN-wide

ETCTN Gastrointestinal Cancer Trials (Open as of 10/12/2026)

Protocol Number	Phase	Protocol Title
10366	I/II	A Phase 1/Randomized Phase 2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
10522	I	A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
10479	I	A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors
10579	I	Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors
10605	I	Phase I Trial of ZEN-3694 in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer
10608	II	A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma
10554	I	Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression
10655	I	Phase I Clinical Trial of CA-4948 in Combination with FOLFOX Plus Bevacizumab as Frontline Treatment in Patients with Metastatic Colorectal Cancer
10670	I	Phase 1 study of 5-fluorouracil in combination with abemaciclib in metastatic, refractory CRC
10703	I/II	A Phase I/II Trial of Sapanisertib in Combination with Cabozantinib in ß-Catenin-Mutated Hepatocellular Carcinoma
10716	I/II	A Phase 1 and Randomized Phase 2 Trial of CX-5461 (Pidnarulex) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer
10733	I	Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
10741	II	Microsatellite Stable Colorectal Cancer with Radiographic Occult Molecular Residual Disease Treated with Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)